MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
Authors:
- Dana C. BorcherdingDBDana C. Borcherding
- Neha V. AminNANeha V. Amin
- Kevin HeKHKevin He
- Xiaochun ZhangXZXiaochun Zhang
- Yang LyuYLYang Lyu
- Carina DehnerCDCarina Dehner
- Himanshi BhatiaHBHimanshi Bhatia
- Angad GothraAGAngad Gothra
- Layla DaudLDLayla Daud
- Peter RuminskiPRPeter Ruminski
- Christine A. PratilasCPChristine A. Pratilas
- Kai PollardKPKai Pollard
Open Access
- 16 February 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (8) , 1592-1604
Abstract
Purpose: Malignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas with limited treatment options and poor survival rates. About half of MPNST cases are associated with the neurofibromatosis type 1 (NF1) cancer predisposition syndrome. Overexpression of TYK2 occurs in the majority of MPNST, implicating TYK2 as a therapeutic target. Experimental Design: The effects of pharmacologic TYK2 inhibition on MPNST cell proliferation and survival were examined using IncuCyte live cell assays in vitro, and downstream actions were analyzed using RNA-sequencing (RNA-seq), qPCR arrays, and validation of protein changes with the WES automated Western system. Inhibition of TYK2 alone and in combination with MEK inhibition was evaluated in vivo using both murine and human MPNST cell lines, as well as MPNST PDX. Results: Pharmacologic inhibition of TYK2 dose-dependently decreased proliferation and induced apoptosis over time. RNA-seq pathway analysis on TYK2 inhibitor–treated MPNST demonstrated decreased expression of cell cycle, mitotic, and glycolysis pathways. TYK2 inhibition resulted in upregulation of the MEK/ERK pathway gene expression, by both RNA-seq and qPCR array, as well as increased pERK1/2 levels by the WES Western system. The compensatory response was tested with dual treatment with TYK2 and MEK inhibitors, which synergistically decreased proliferation and increased apoptosis in vitro. Finally, combination therapy was shown to inhibit growth of MPNST in multiple in vivo models. Conclusions: These data provide the preclinical rationale for the development of a phase I clinical trial of deucravacitinib and mirdametinib in NF1-assosciated MPNST.Keywords
All Related Versions
Funding Information
- Congressionally Directed Medical Research Programs (W81XWH-20-1-0148)
- Doris Duke Charitable Foundation
- Neurofibromatosis Therapeutic Acceleration Program
- St. Louis Men's Group Against Cancer
This publication has 50 references indexed in Scilit:
- Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath TumorsClinical Cancer Research, 2013
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapyNature, 2012
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for MyelofibrosisNew England Journal of Medicine, 2012
- Quantitative Phospho-Proteomic Profiling of Hepatocyte Growth Factor (HGF)-MET Signaling in Colorectal CancerJournal of Proteome Research, 2011
- Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitorsHaematologica, 2011
- Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)Cancer Research, 2010
- V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathwayProceedings of the National Academy of Sciences, 2009
- Proteomic identification of differentially-expressed proteins in squamous cervical cancerGynecologic Oncology, 2009
- Protein Expression Profiling of Breast Cancer Cells by Dissociable Antibody Microarray (DAMA) StainingMolecular & Cellular Proteomics, 2008
- Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administrationCancer Chemotherapy and Pharmacology, 2006